NCT07469774 2026-03-13
BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Biocity Biopharmaceutics Co., Ltd.
Phase 1/2 Not yet recruiting
Biocity Biopharmaceutics Co., Ltd.
InxMed (Shanghai) Co., Ltd.
Pyrotech Therapeutics, Inc.
Dong-A ST Co., Ltd.